InvestorsHub Logo
Followers 21
Posts 1025
Boards Moderated 0
Alias Born 04/07/2008

Re: midastouch017 post# 25

Sunday, 01/05/2020 3:35:49 PM

Sunday, January 05, 2020 3:35:49 PM

Post# of 964
I guess no-one will mind us talking a little further about off-topic companies on this board :)

Thanks for raisin that and just read the article and it does a good job of covering the key points. Interesting he has some of his grammar at different points in time. He clearly knows about the RHB-106 return to RedHill that just happened, but apparently doesn't know that Aemcolo was already officially launched earlier in Q42019.

Something I find interesting too between RedHill and Protalix is that, RedHill has a product for IBS (Bekinda) and Crohn's (RHB-104), where Protalix in OPRX-106 also has a product to tackle both of these. Perhaps they could share the market if RedHill goes for less severe patients, and Protalix goes for more severe patients, particularly as inside OPRX-106 is the most expensive go-to product, anti-TNFalpha. I expect very good things from OPRX-106, and especially if given to patients longer than the Phase II trial of 8 weeks.

That they reached 67% Clinical Response and 28% Complete Remission, in 8 weeks is very well done. And with the added benefit of no real adverse events and the elimination of systemic exposure of the drug. Looking forward to the next 3-4 years. Hoping that's all I'll need :)
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.